Full Product Name
PAX6 siRNA (Rat)
Product Synonym Names
PAX-6; SEY; Paired box protein Pax-6; Oculorhombin
Product Gene Name
PAX6 sirna
[Similar Products]
Research Use Only
For Research Use Only. Not for use in diagnostic procedures.
3D Structure
ModBase 3D Structure for P63016
Specificity
PAX6 siRNA (Rat) is a target-specific 19-23 nt siRNA oligo duplexes designed to knock down gene expression.
Purity/Purification
> 97%
Form/Format
Lyophilized powder
Quality Control
Oligonucleotide synthesis is monitored base by base through trityl analysis to ensure appropriate coupling efficiency. The oligo is subsequently purified by affinity-solid phase extraction. The annealed RNA duplex is further analyzed by mass spectrometry to verify the exact composition of the duplex. Each lot is compared to the previous lot by mass spectrometry to ensure maximum lot-to-lot consistency.
Directions for Use
We recommends transfection with 100 nM siRNA 48 to 72 hours prior to cell lysis. Before resuspending, briefly centrifuge the tube to ensure the lyophilized siRNA is at the bottom of the tube. Resuspend the siRNA oligos to an appropriate concentration with DEPC water. For each vial, suitable for 250 transfections in 24 well plate (20 pmol for each well).
Components
We offer pre-designed sets of 3 different target-specific siRNA oligo duplexes of rat PAX6 gene. Each vial contains 5 nmol of lyophilized siRNA. The duplexes can be transfected individually or pooled together to achieve knockdown of the target gene, which is most commonly assessed by qPCR or western blot. Our siRNA oligos are also chemically modified (2'-OMe) at no extra charge for increased stability and enhanced knockdown in vitro and in vivo.
Preparation and Storage
Shipped at 4 degree C. Store at -20 degree C for one year.
Negative Control
siRNA Negative Control (Catalog# MBS8241404) is a non-targeting 21 nt siRNA recommended as a negative control for experiments using targeted siRNA transfection.
Other Notes
Small volumes of PAX6 sirna vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.
Related Product Information for
PAX6 sirna
siRNA to inhibit PAX6 expression using RNA interference
Applications Tested/Suitable for PAX6 sirna
RNA Interference (RNAi)
NCBI/Uniprot data below describe general gene information for PAX6. It may not necessarily be applicable to this product.
NCBI Accession #
NP_037133.1
[Other Products]
NCBI GenBank Nucleotide #
NM_013001.2
[Other Products]
UniProt Primary Accession #
P63016
[Other Products]
UniProt Secondary Accession #
P32117; P70601; Q62222; Q64037; Q6QHS5; Q701Q8; A1A5N7[Other Products]
UniProt Related Accession #
P63016[Other Products]
Molecular Weight
48,263 Da
NCBI Official Full Name
paired box protein Pax-6
NCBI Official Synonym Full Names
paired box 6
NCBI Official Symbol
Pax6 [Similar Products]
NCBI Protein Information
paired box protein Pax-6
UniProt Protein Name
Paired box protein Pax-6
UniProt Synonym Protein Names
Oculorhombin
Protein Family
Paired box protein
UniProt Gene Name
Pax6 [Similar Products]
UniProt Synonym Gene Names
Pax-6; Sey [Similar Products]
UniProt Entry Name
PAX6_RAT
NCBI Summary for PAX6
homeodomain (HD)-containing transcription factor; may play a role in the differentiation of the hindbrain somatic (SM) motoneurones and V1 interneurones in the hindbrain and/or spinal cord [RGD, Feb 2006]
UniProt Comments for PAX6
PAX6: Transcription factor with important functions in the development of the eye, nose, central nervous system and pancreas. Required for the differentiation of pancreatic islet alpha cells. Competes with PAX4 in binding to a common element in the glucagon, insulin and somatostatin promoters. Regulates specification of the ventral neuron subtypes by establishing the correct progenitor domains. Isoform 5a appears to function as a molecular switch that specifies target genes. Defects in PAX6 are the cause of aniridia (AN). A congenital, bilateral, panocular disorder characterized by complete absence of the iris or extreme iris hypoplasia. Aniridia is not just an isolated defect in iris development but it is associated with macular and optic nerve hypoplasia, cataract, corneal changes, nystagmus. Visual acuity is generally low but is unrelated to the degree of iris hypoplasia. Glaucoma is a secondary problem causing additional visual loss over time. Defects in PAX6 are a cause of Peters anomaly (PAN). Peters anomaly consists of a central corneal leukoma, absence of the posterior corneal stroma and Descemet membrane, and a variable degree of iris and lenticular attachments to the central aspect of the posterior cornea. Defects in PAX6 are a cause of foveal hypoplasia (FOVHYP). Foveal hypoplasia can be isolated or associated with presenile cataract. Inheritance is autosomal dominant. Defects in PAX6 are a cause of keratitis hereditary (KERH). An ocular disorder characterized by corneal opacification, recurrent stromal keratitis and vascularization. Defects in PAX6 are a cause of coloboma of iris choroid and retina (COI); also known as uveoretinal coloboma. Ocular colobomas are a set of malformations resulting from abnormal morphogenesis of the optic cup and stalk, and the fusion of the fetal fissure (optic fissure). Severe colobomatous malformations may cause as much as 10% of the childhood blindness. The clinical presentation of ocular coloboma is variable. Some individuals may present with minimal defects in the anterior iris leaf without other ocular defects. More complex malformations create a combination of iris, uveoretinal and/or optic nerve defects without or with microphthalmia or even anophthalmia. Defects in PAX6 are a cause of coloboma of optic nerve (COLON). Defects in PAX6 are a cause of bilateral optic nerve hypoplasia (BONH); also known as bilateral optic nerve aplasia. A congenital anomaly in which the optic disc appears abnormally small. It may be an isolated finding or part of a spectrum of anatomic and functional abnormalities that includes partial or complete agenesis of the septum pellucidum, other midline brain defects, cerebral anomalies, pituitary dysfunction, and structural abnormalities of the pituitary. Defects in PAX6 are a cause of aniridia cerebellar ataxia and mental deficiency (ACAMD); also known as Gillespie syndrome. A rare condition consisting of partial rudimentary iris, cerebellar impairment of the ability to perform coordinated voluntary movements, and mental retardation. Belongs to the paired homeobox family. 3 isoforms of the human protein are produced by alternative splicing.
Protein type: Transcription factor; DNA-binding; Motility/polarity/chemotaxis
Cellular Component: nucleoplasm; transcription factor complex; cell; nuclear chromatin; cytoplasm; intracellular; nucleus
Molecular Function: histone acetyltransferase binding; protein binding; DNA binding; AT DNA binding; sequence-specific DNA binding; ubiquitin protein ligase binding; double-stranded DNA binding; chromatin binding; protein kinase binding; transcription factor binding; transcription factor activity
Biological Process: regulation of neuron differentiation; multicellular organismal development; positive regulation of transcription, DNA-dependent; cell fate determination; telencephalon regionalization; glucose homeostasis; regulation of cell migration; anterior/posterior pattern formation; epithelial cell development; positive regulation of epithelial cell differentiation; pallium development; neural crest cell migration; hindbrain development; positive regulation of neuroblast proliferation; camera-type eye development; cell fate commitment; transcription, DNA-dependent; positive regulation of cell fate specification; oligodendrocyte cell fate specification; interkinetic nuclear migration; keratinocyte differentiation; regulation of transcription from RNA polymerase II promoter; forebrain-midbrain boundary formation; eye photoreceptor cell development; negative regulation of neuron differentiation; regulation of gene expression; retina development in camera-type eye; rhombomere morphogenesis; regulation of transcription from RNA polymerase II promoter involved in somatic motor neuron fate commitment; forebrain anterior/posterior pattern formation; positive regulation of transcription from RNA polymerase II promoter; lens development in camera-type eye; transcription from RNA polymerase II promoter; axon guidance; regulation of asymmetric cell division; neuron migration; forebrain dorsal/ventral pattern formation; dorsal/ventral axis specification; negative regulation of transcription from RNA polymerase II promoter; cerebral cortex regionalization; negative regulation of cell proliferation; regulation of neurogenesis; establishment of mitotic spindle orientation; negative regulation of protein amino acid phosphorylation; regulation of transcription, DNA-dependent; astrocyte differentiation; forebrain development; salivary gland morphogenesis; lacrimal gland development; cell differentiation; regulation of timing of cell differentiation; negative regulation of epithelial cell proliferation; blood vessel development; smoothened signaling pathway; olfactory bulb development; dorsal/ventral pattern formation; axonogenesis; protein localization in organelle; pituitary gland development; commitment of a neuronal cell to a specific type of neuron in the forebrain; regulation of transcription from RNA polymerase II promoter involved in ventral spinal cord interneuron specification; regulation of transcription from RNA polymerase II promoter involved in spinal cord motor neuron fate specification; brain development; embryonic camera-type eye morphogenesis
Research Articles on PAX6
1. Up-regulation of Pax6 in neural progenitor cells plays an essential role in valproate-induced glutamatergic differentiation.
Precautions
All of MyBioSource's Products are for scientific laboratory research purposes and are not for diagnostic, therapeutics, prophylactic or in vivo use. Through your purchase, you expressly represent and warrant to MyBioSource that you will properly test and use any Products purchased from MyBioSource in accordance with industry standards. MyBioSource and its authorized distributors reserve the right to refuse to process any order where we reasonably believe that the intended use will fall outside of our acceptable guidelines.
Disclaimer
While every efforts were made to ensure the accuracy of the information provided in this datasheet, MyBioSource will not be liable for any omissions or errors contained herein. MyBioSource reserves the right to make changes to this datasheet at any time without prior notice.
It is the responsibility of the customer to report product performance issues to MyBioSource within 30 days of receipt of the product. Please visit our Terms & Conditions page for more information.
